ZIM
SCMP

Zacks Investment Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Zacks Investment Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-16,405
Closed -$180K – 750
2017
Q1 		$180K Buy
+16,405
New +$190K ﹤0.01% 602
2016
Q3 		– Sell
-10,050
Closed -$110K – 771
2016
Q2 		$110K Buy
+10,050
New +$112K ﹤0.01% 607
2015
Q2 		– Sell
-10,668
Closed -$166K – 775
2015
Q1 		$166K Buy
+10,668
New +$165K 0.01% 602

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zacks Investment Management's SCMP Position: Q2 2017 in Review

Zacks Investment Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2017, closing a stake of 16,405 shares — an estimated $180K sold.

Zacks Investment Management first reported a position in SCMP in Q1 2015 and held it in 3 quarters. The position peaked at $180K in Q1 2017. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

  • Zacks Investment Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Zacks Investment Management sold 16,405 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $180K.
  • Zacks Investment Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
  • Zacks Investment Management's Sucampo Pharmaceuticals, Inc. position peaked at $180K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on Zacks Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.